Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 19, 2021 Filed Jul 22, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,895 | $6.32 | $24,616.40 |
DisclosureSEC source: 0001209191-21-047649 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| July 14, 2021 Filed Jul 20, 2021 01:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-047303 · doc4.xml · derivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 2,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 14, 2021 Filed Jul 20, 2021 01:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
SaleCommon Stock | 2,500 | $36.80 | $92,000.00 |
DisclosureSEC source: 0001209191-21-047303 · doc4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| July 14, 2021 Filed Jul 20, 2021 01:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionCommon Stock | 2,500 | $7.80 | $19,500.00 |
DisclosureSEC source: 0001209191-21-047303 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| July 12, 2021 Filed Jul 15, 2021 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 1,501 | $38.24 | $57,398.24 |
DisclosureSEC source: 0001209191-21-046710 · doc4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,716,960 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.00 to 38.85, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 08, 2021 Filed Jul 8, 2021 21:00 UTC |
ADAMS R MARKChief Operating Officer
|
SaleCommon Stock | 2,254 | $36.30 | $81,820.20 |
DisclosureSEC source: 0001209191-21-046083 · doc4.xml · nonDerivative · entry 2 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,979 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.99 to 36.65, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:00 UTC |
ADAMS R MARKChief Operating Officer
|
SaleCommon Stock | 871 | $39.42 | $34,334.82 |
DisclosureSEC source: 0001209191-21-046083 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,233 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 01:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-046082 · doc4.xml · derivative · entry 7 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 01:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 3,514 | $39.20 | $137,748.80 |
DisclosureSEC source: 0001209191-21-046082 · doc4.xml · nonDerivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.875 to 39.42, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 01:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 6,486 | $38.17 | $247,570.62 |
DisclosureSEC source: 0001209191-21-046082 · doc4.xml · nonDerivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,118 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.775 to 38.735, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 01:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $6.55 | $65,500.00 |
DisclosureSEC source: 0001209191-21-046082 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| July 06, 2021 Filed Jul 9, 2021 01:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-046082 · doc4.xml · derivative · entry 6 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 06, 2021 Filed Jul 9, 2021 01:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 10,000 | $38.83 | $388,300.00 |
DisclosureSEC source: 0001209191-21-046082 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.32 to 39.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 06, 2021 Filed Jul 9, 2021 01:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $6.55 | $65,500.00 |
DisclosureSEC source: 0001209191-21-046082 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,354 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-21-044630 · doc4.xml · derivative · entry 8 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,334 Underlying: Common Stock · 1,354 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,771 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-044630 · doc4.xml · derivative · entry 7 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,938 Underlying: Common Stock · 1,771 shares Expires 2028-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,042 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-044630 · doc4.xml · derivative · entry 6 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,917 Underlying: Common Stock · 1,042 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 395 | $42.13 | $16,641.35 |
DisclosureSEC source: 0001209191-21-044630 · doc4.xml · nonDerivative · entry 5 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,036 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 3,772 | $41.35 | $155,972.20 |
DisclosureSEC source: 0001209191-21-044630 · doc4.xml · nonDerivative · entry 4 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,431 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.00 to 41.58, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,354 | $31.71 | $42,935.34 |
DisclosureSEC source: 0001209191-21-044630 · doc4.xml · nonDerivative · entry 3 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,771 | $6.55 | $11,600.05 |
DisclosureSEC source: 0001209191-21-044630 · doc4.xml · nonDerivative · entry 2 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,042 | $7.80 | $8,127.60 |
DisclosureSEC source: 0001209191-21-044630 · doc4.xml · nonDerivative · entry 1 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:00 UTC |
Palaniappan JyotiSVP, Diagnostics, T-Detect
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,301 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001209191-21-042288 · doc4.xml · derivative · entry 6 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,344 Underlying: Common Stock · 1,301 shares Expires 2030-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:00 UTC |
Palaniappan JyotiSVP, Diagnostics, T-Detect
|
SaleCommon Stock | 1,301 | $39.80 | $51,779.80 |
DisclosureSEC source: 0001209191-21-042288 · doc4.xml · nonDerivative · entry 4 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,158 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.59 to 40.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:00 UTC |
Palaniappan JyotiSVP, Diagnostics, T-Detect
|
Exercise / conversionCommon Stock | 1,301 | $22.55 | $29,337.55 |
DisclosureSEC source: 0001209191-21-042288 · doc4.xml · nonDerivative · entry 3 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| June 17, 2021 Filed Jun 18, 2021 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 4,255 | $39.76 | $169,178.80 |
DisclosureSEC source: 0001209191-21-041790 · doc4.xml · nonDerivative · entry 5 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,718,461 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.35 to 40.09, inclusive. Read SEC document |
| June 17, 2021 Filed Jun 18, 2021 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 1,000 | $38.55 | $38,550.00 |
DisclosureSEC source: 0001209191-21-041790 · doc4.xml · nonDerivative · entry 4 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,722,716 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.06 to 39.04, inclusive. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC |
ADAMS R MARKChief Operating Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 14,583 | $0.00 Strike: $28.10 | $0.00 |
DisclosureSEC source: 0001209191-21-042290 · doc4.xml · derivative · entry 3 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,417 Underlying: Common Stock · 14,583 shares Expires 2030-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on April 6, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC |
ADAMS R MARKChief Operating Officer
|
SaleCommon Stock | 14,583 | $40.00 | $583,320.00 |
DisclosureSEC source: 0001209191-21-042290 · doc4.xml · nonDerivative · entry 2 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,104 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC |
ADAMS R MARKChief Operating Officer
|
Exercise / conversionCommon Stock | 14,583 | $28.10 | $409,782.30 |
DisclosureSEC source: 0001209191-21-042290 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC |
Palaniappan JyotiSVP, Diagnostics, T-Detect
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 651 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001209191-21-042288 · doc4.xml · derivative · entry 5 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,345 Underlying: Common Stock · 651 shares Expires 2030-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC |
Palaniappan JyotiSVP, Diagnostics, T-Detect
|
SaleCommon Stock | 651 | $40.00 | $26,040.00 |
DisclosureSEC source: 0001209191-21-042288 · doc4.xml · nonDerivative · entry 2 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,158 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC |
Palaniappan JyotiSVP, Diagnostics, T-Detect
|
Exercise / conversionCommon Stock | 651 | $22.55 | $14,680.05 |
DisclosureSEC source: 0001209191-21-042288 · doc4.xml · nonDerivative · entry 1 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,354 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-21-042291 · doc4.xml · derivative · entry 7 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,688 Underlying: Common Stock · 1,354 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,771 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-042291 · doc4.xml · derivative · entry 6 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,709 Underlying: Common Stock · 1,771 shares Expires 2028-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,041 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-042291 · doc4.xml · derivative · entry 5 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,959 Underlying: Common Stock · 1,041 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 4,166 | $40.00 | $166,640.00 |
DisclosureSEC source: 0001209191-21-042291 · doc4.xml · nonDerivative · entry 4 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,036 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,354 | $31.71 | $42,935.34 |
DisclosureSEC source: 0001209191-21-042291 · doc4.xml · nonDerivative · entry 3 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,771 | $6.55 | $11,600.05 |
DisclosureSEC source: 0001209191-21-042291 · doc4.xml · nonDerivative · entry 2 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,041 | $7.80 | $8,119.80 |
DisclosureSEC source: 0001209191-21-042291 · doc4.xml · nonDerivative · entry 1 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 00:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-042289 · doc4.xml · derivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,500 Underlying: Common Stock · 4,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 00:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
SaleCommon Stock | 4,000 | $40.00 | $160,000.00 |
DisclosureSEC source: 0001209191-21-042289 · doc4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 00:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionCommon Stock | 4,000 | $7.80 | $31,200.00 |
DisclosureSEC source: 0001209191-21-042289 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| June 16, 2021 Filed Jun 18, 2021 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 4,745 | $38.13 | $180,926.85 |
DisclosureSEC source: 0001209191-21-041790 · doc4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,723,716 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.00 to 38.46, inclusive. Read SEC document |
| June 15, 2021 Filed Jun 18, 2021 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 900 | $39.23 | $35,307.00 |
DisclosureSEC source: 0001209191-21-041790 · doc4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,728,461 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.00 to 39.42, inclusive. Read SEC document |
| June 15, 2021 Filed Jun 18, 2021 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 19,100 | $38.22 | $730,002.00 |
DisclosureSEC source: 0001209191-21-041790 · doc4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,729,361 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.00 to 38.91, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 19:00 UTC |
ADAMS R MARKChief Operating Officer
|
SaleCommon Stock | 8,914 | $38.77 | $345,595.78 |
DisclosureSEC source: 0001209191-21-041088 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,104 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.31 to 39.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 23:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-041089 · doc4.xml · derivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,500 Underlying: Common Stock · 2,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 23:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
SaleCommon Stock | 2,500 | $38.56 | $96,400.00 |
DisclosureSEC source: 0001209191-21-041089 · doc4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 23:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionCommon Stock | 2,500 | $7.80 | $19,500.00 |
DisclosureSEC source: 0001209191-21-041089 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.